The anti-CD40 monoclonal antibody selicrelumab is another approach to reprogram TAMs to an M1-like phenotype and enhance phagocytosis, whose main mode of action may be the induction of increased tumor-specific antigen presentation via activation of antigen-presenting cells, resulting in the production of cytotoxic T cells directed against the tumor (115–117). The gene discussed is CD40; the disease is neoplasm.